Loading...
XNASCOLL
Market cap1.06bUSD
Jan 10, Last price  
32.91USD
1D
-1.29%
1Q
-12.75%
Jan 2017
111.37%
IPO
154.13%
Name

Collegium Pharmaceutical Inc

Chart & Performance

D1W1MN
XNAS:COLL chart
P/E
22.04
P/S
1.87
EPS
1.49
Div Yield, %
0.00%
Shrs. gr., 5y
4.86%
Rev. gr., 5y
15.11%
Revenues
567m
+22.17%
0001,711,00028,476,000280,413,000296,701,000310,016,000276,868,000463,933,000566,767,000
Net income
48m
P
-16,197,000-17,917,000-27,255,000-94,176,000-74,865,000-39,128,000-8,148,00026,752,00071,517,000-25,002,00048,155,000
CFO
275m
+121.16%
-16,530,000-17,947,000-21,567,000-75,053,000-67,018,000169,390,00027,783,00093,942,000103,557,000124,230,000274,749,000
Earnings
Feb 20, 2025

Profile

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
URL
https://www.collegiumpharma.com/
IPO date
May 07, 2015
Employees
207
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
566,767
22.17%
463,933
67.56%
Cost of revenue
399,806
430,614
Unusual Expense (Income)
NOPBT
166,961
33,319
NOPBT Margin
29.46%
7.18%
Operating Taxes
27,578
(3,845)
Tax Rate
16.52%
NOPAT
139,383
37,164
Net income
48,155
-292.60%
(25,002)
-134.96%
Dividends
Dividend yield
Proceeds from repurchase of equity
(75,000)
(2,252)
BB yield
5.83%
0.29%
Debt
Debt current
185,309
163,612
Long-term debt
503,198
717,399
Deferred revenue
Other long-term liabilities
(6,124)
Net debt
377,959
704,776
Cash flow
Cash from operating activities
274,749
124,230
CAPEX
(461)
(1,622)
Cash from investing activities
(70,812)
(573,691)
Cash from financing activities
(140,178)
436,723
FCF
283,552
(101,882)
Balance
Cash
310,548
173,688
Long term investments
2,547
Excess cash
282,210
153,038
Stockholders' equity
(233,137)
(281,307)
Invested Capital
1,103,839
1,344,584
ROIC
11.39%
3.53%
ROCE
19.18%
3.13%
EV
Common stock shares outstanding
41,788
33,829
Price
30.78
32.67%
23.20
24.20%
Market cap
1,286,238
63.88%
784,844
2.36%
EV
1,664,197
1,489,620
EBITDA
316,217
172,258
EV/EBITDA
5.26
8.65
Interest
83,339
63,213
Interest/NOPBT
49.92%
189.72%